Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 213536
Company: DR REDDYS LABS SA
Company: DR REDDYS LABS SA
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
REZIPRES | EPHEDRINE HYDROCHLORIDE | 23.5MG/5ML (4.7MG/ML) | SOLUTION;INTRAVENOUS | Discontinued | None | Yes | No |
REZIPRES | EPHEDRINE HYDROCHLORIDE | 47MG/ML (47MG/ML) | SOLUTION;INTRAVENOUS | Discontinued | None | Yes | No |
REZIPRES | EPHEDRINE HYDROCHLORIDE | 47MG/5ML (9.4MG/ML) | SOLUTION;INTRAVENOUS | Discontinued | None | Yes | No |
REZIPRES | EPHEDRINE HYDROCHLORIDE | 47MG/10ML (4.7MG/ML) | SOLUTION;INTRAVENOUS | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
06/14/2021 | ORIG-1 | Approval | Type 5 - New Formulation or New Manufacturer | STANDARD |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213536s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213536Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213536Orig1s000TOC.cfm |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
06/14/2021 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213536s000lbl.pdf |